Evolus, Inc. (EOLS)

Evolus, Inc.'s stock price has been impacted by several events in the past six months, including reporting quarterly losses and missing revenue estimates. Analyst firms have adjusted price targets, but the stock maintains a consensus rating of 'Moderate Buy' with a potential upside from its current price.

While specific demand seasonality for Evolus, Inc.'s products is not explicitly detailed, the company operates in the cash-pay aesthetic market, which can exhibit seasonal patterns. Demand for aesthetic procedures can sometimes exhibit seasonal patterns, with potential increases around holidays or specific times of the year when individuals may be more inclined to seek cosmetic treatments.

Evolus, Inc. is a performance beauty company in the healthcare sector, focusing on specialty and generic drug manufacturing. Headquartered in Newport Beach, California, it delivers products to the cash-pay aesthetic market, including Jeuveau and the Evolysse collection of injectable hyaluronic acid gels.

Evolus, Inc. has a global geographic footprint, delivering its products to markets in the United States, Canada, Europe (including Great Britain, Germany, Austria, and Italy), and Australia. The company is actively pursuing further geographic expansion.

Evolus aims to enhance its market share and consumer retention through strong loyalty engagement and digital engagement programs. The company's Jeuveau U.S. market share strengthened to 14% year-to-date as of Q3 2025. The Evolysse filler line also delivered $5.7 million in Q3 2025, exceeding the prior-quarter run rate.

Evolus, Inc. has significant institutional ownership, with 273 institutional owners and shareholders holding a total of 59,237,061 shares. Institutions hold 90.69% of the stock, while insiders hold 5.90%.